The digital spirometers market size was valued at USD 633.84 million in 2025 and is projected to grow from USD 632.64 million in 2026 to USD 1034.48 million by 2034, registering a CAGR of 5.64% during the forecast period (2026–2034). North America dominated the digital spirometers market with a market share of 42.38% in 2025.
Digital spirometers are medical devices used to measure lung function by assessing airflow, lung volume, and breathing capacity during respiratory testing. These devices provide accurate, real-time results that support the diagnosis and monitoring of respiratory disorders, including asthma, chronic obstructive pulmonary disease, and other lung conditions. They are widely used in hospitals, clinics, diagnostic centers, and home healthcare settings.
The digital spirometers market demand is driven by the rising prevalence of respiratory diseases, growing emphasis on early diagnosis, and expanding adoption of portable diagnostic devices. Technological advancements, increasing healthcare investments, and wider access to respiratory care are further contributing to digital spirometers market growth.
Download a Free Sample to Explore Detailed Market Insights
The digital spirometers market is moderately exposed to supply chain disruptions due to its reliance on electronic components, sensors, semiconductors, and precision manufacturing materials sourced from global suppliers. Disruptions in component availability, logistics networks, and cross-border trade have increased production costs, extended lead times, and delayed product deliveries across key markets. These challenges have affected manufacturers' ability to meet rising demand from hospitals, diagnostic centers, and home healthcare providers, prompting greater focus on supplier diversification, regional manufacturing, and inventory optimization. The market is experiencing a capacity-constrained recovery, supported by improving component availability, strengthened supply networks, and continued investments in manufacturing resilience and digital healthcare infrastructure.
The increasing preference for decentralized healthcare is driving the adoption of portable digital spirometers for home based respiratory monitoring. Patients with chronic respiratory diseases are increasingly using compact, connected spirometers to track lung function outside clinical settings, improving disease management and reducing hospital visits. This transition is supporting continuous patient monitoring and expanding the use of digital respiratory diagnostics.
The shift toward connected healthcare is accelerating the integration of digital spirometers with cloud-based platforms and telehealth ecosystems. Healthcare providers are increasingly adopting devices that enable automatic data storage, remote access, and seamless sharing of pulmonary function reports, improving clinical decision-making and patient follow-up. This trend is enhancing workflow efficiency while supporting remote respiratory care and population health management. For example, ndd Medical Technologies' EasyOne Connect integrates spirometry data with cloud-enabled clinical systems to facilitate remote monitoring and electronic health record connectivity.
The digital spirometers market forecasts sustained investments toward connected respiratory diagnostics, cloud-based pulmonary monitoring, and AI-enabled spirometry platforms. Investments such as MIR's expansion under Quadrivio Group's Silver Economy Fund reflect growing industry focus on strengthening digital health capabilities, expanding global access to connected spirometry solutions, and supporting remote respiratory care.
In January 2025, MIR (Medical International Research), a leading digital spirometer manufacturer, entered a new ownership phase through investment by Quadrivio Group's Silver Economy Fund. The investment supports international expansion, digital health capabilities, and further development of MIR's connected spirometry portfolio, strengthening innovation and commercialization within the digital spirometers market.
Growing Adoption of Occupational Lung Health Surveillance Programs and Expansion of Clinical Trials for Respiratory Therapies Drives Market
The expansion of occupational lung health surveillance across mining, construction, manufacturing, and chemical industries is increasing demand for digital spirometers. Employers are conducting routine pulmonary function testing to comply with workplace safety regulations and detect respiratory impairment at an early stage among workers exposed to dust and hazardous fumes.
The increasing number of clinical trials for asthma, COPD, pulmonary fibrosis, cystic fibrosis, and other respiratory diseases is creating strong demand for highly accurate digital spirometers. Pharmaceutical companies and contract research organizations require standardized, ATS/ERS-compliant spirometry systems to generate reliable pulmonary function data across multi-center studies. This is encouraging manufacturers to develop connected devices with automated quality checks and centralized data management capabilities, expanding the adoption of advanced digital spirometry solutions. For example, digital spirometers are extensively used in global COPD and asthma drug trials to monitor forced expiratory volume and other pulmonary endpoints consistently across study sites.
High Dependence on Reusable Sensor Calibration and Data Privacy & Cybersecurity Concerns Restrain Market Expansion
Digital spirometers require periodic calibration, sensor validation, and maintenance to maintain measurement accuracy and comply with respiratory testing standards. The need for regular servicing, replacement of components, and technical support increases operational costs for healthcare facilities, particularly smaller clinics and diagnostic centers. The 2025 ATS/ERS spirometry technical standards update continued to emphasize equipment accuracy verification and quality control requirements, increasing compliance obligations for users and limiting adoption among cost-sensitive providers.
The increasing integration of digital spirometers with cloud platforms, mobile applications, and remote monitoring systems creates concerns regarding patient data security and regulatory compliance. Healthcare providers must invest in secure data transmission, software updates, and cybersecurity measures, which increases implementation complexity and costs.
Integration of Digital Spirometers with AI-based Respiratory Analytics and Expansion of Pediatric Respiratory Diagnostics Offer Growth Opportunities to Market Players
The integration of artificial intelligence and predictive analytics into digital spirometry creates opportunities for device manufacturers to offer advanced respiratory assessment solutions. AI-enabled spirometers can analyze lung function patterns, improve test interpretation, and support early identification of respiratory deterioration, creating value for hospitals, telehealth providers, and chronic disease management programs. This opportunity is expected to expand as healthcare systems move toward personalized and preventive respiratory care models.
The rising prevalence of childhood respiratory disorders creates opportunities for digital spirometer manufacturers to develop pediatric-focused solutions with improved usability and accuracy. Traditional spirometry challenges in children are increasing demand for devices with automated coaching and interactive guidance features. The World Health Organization reported that asthma affected approximately 262 million people globally, with a significant burden among children, supporting the need for early respiratory assessment and long-term monitoring solutions. This opportunity is expected to expand as pediatric respiratory screening programs grow worldwide.
Limited Clinical Awareness and Competition from Low-cost Conventional Spirometers Challenges Market Growth
Limited familiarity with advanced digital spirometry solutions among primary care providers and technicians slows adoption beyond specialized respiratory centers. Inadequate training in performing high-quality spirometry tests and interpreting digital outputs reduces confidence in device utilization, particularly in emerging healthcare markets. The Global Initiative for Chronic Obstructive Lung Disease 2025 strategy report continues to emphasize the importance of proper spirometry use and interpretation, highlighting ongoing skill gaps that restrict wider implementation.
The availability of traditional handheld and mechanical spirometers at lower costs creates pricing pressure for advanced digital spirometer manufacturers. Healthcare facilities with limited budgets may continue using basic devices despite the benefits of digital connectivity, automated interpretation, and remote monitoring capabilities. This cost-driven preference slows replacement cycles and limits penetration of premium digital spirometry solutions, especially in developing healthcare systems.
The handheld digital spirometers segment accounted for a share of 54.39% in 2025, owing to compact design, battery-powered operation, and suitability for point-of-care respiratory testing. These devices support rapid lung function assessment across clinics, emergency settings, and primary care facilities.
The smartphone connected digital spirometers segment is expected to grow at a CAGR of around 6.47% during the forecast period, driven by Bluetooth-enabled connectivity, mobile application integration, and remote data-sharing capabilities. These devices support virtual respiratory care by enabling patients to perform spirometry tests outside traditional healthcare facilities.
The COPD segment accounted for a share of 46.31% in 2025, owing to frequent lung function monitoring requirements, increasing disease progression assessment needs, and long-term therapy evaluation. Digital spirometers help clinicians track FEV1 changes and optimize treatment strategies for COPD patients.
The asthma segment is expected to grow at a CAGR of 6.82% during the forecast period, fueled by increasing demand for personalized symptom monitoring, pediatric respiratory assessment, and home-based disease management. Digital spirometers enable patients to track breathing patterns and support timely intervention during asthma exacerbations.
By end user, hospitals accounted for a share of 47.53% in 2025 due to availability of pulmonary laboratories, higher diagnostic testing volumes, and adoption of advanced respiratory care infrastructure. Hospitals utilize digital spirometers for accurate diagnosis, preoperative evaluation, and continuous monitoring of respiratory conditions.
The ambulatory surgical centers segment is expected to grow at a CAGR of 9.10% during the forecast period, driven by increasing outpatient procedures, pre-surgical pulmonary screening, and demand for compact diagnostic equipment. Digital spirometers support efficient respiratory evaluation within fast-paced ambulatory surgical workflows.
North America: Market Dominance Led by Strong Adoption of Digital Respiratory Diagnostics and High Availability of Specialized Respiratory Clinics
The North America digital spirometers market accounted for the largest regional share of 42.38% in 2025, driven by strong adoption of digital respiratory diagnostics, increasing prevalence of chronic respiratory disorders, and widespread integration of connected healthcare technologies. The region benefits from advanced pulmonary care infrastructure, established reimbursement systems, and high availability of specialized respiratory clinics. According to the Centers for Disease Control and Prevention, millions of adults in the US live with asthma and COPD, supporting continuous demand for lung function monitoring solutions.
The US digital spirometers market was valued at USD 233.26 million in 2025, driven by increasing adoption of remote respiratory monitoring solutions, rising demand for home-based pulmonary assessments, and integration of digital spirometry with telehealth platforms. Healthcare providers are increasingly utilizing connected spirometry devices for COPD, asthma, and pulmonary rehabilitation programs. The country’s strong presence of respiratory care centers, academic hospitals, and digital health initiatives continues to support demand for advanced spirometry technologies.
The digital spirometers market in Canada was valued at USD 34.85 million in 2025, supported by growing emphasis on chronic respiratory disease management, expansion of virtual healthcare services, and increasing adoption of portable diagnostic devices. Healthcare providers are focusing on improving access to respiratory testing across geographically dispersed regions, encouraging the use of connected and portable spirometry solutions. The country’s growing telemedicine infrastructure and public healthcare focus on early disease detection create favorable conditions for digital spirometer adoption.
Asia Pacific: Fastest Growth Driven by Increasing Adoption of Telehealth Services and Increasing Adoption of Domestic Digital Diagnostic Equipment
The Asia Pacific digital spirometers market is expected to grow at a CAGR of 7.60% during the forecast period, showcasing the fastest regional growth. Growth is supported by increasing adoption of telehealth services, expansion of primary respiratory screening programs, and rising availability of portable diagnostic devices. Governments are strengthening digital healthcare access to improve chronic disease management. According to the WHO, over 1 billion people in the Western Pacific region are affected by chronic respiratory diseases and risk factors, supporting demand for lung function monitoring technologies.
The China digital spirometers market was valued at USD 35.53 million in 2025, supported by rapid development of county level healthcare facilities, expansion of respiratory disease screening programs, and increasing adoption of domestic digital diagnostic equipment. Healthcare reforms are improving access to pulmonary testing beyond major cities. According to China’s National Health Commission, more than 100 million people in China are affected by chronic respiratory diseases, creating demand for accessible lung function assessment solutions.
The India digital spirometers market was valued at USD 18.17 million in 2025, fueled by increasing integration of respiratory diagnostics into primary healthcare centers, rising urban air pollution-related respiratory concerns, and expansion of affordable portable diagnostic solutions. Government healthcare initiatives are improving access to early respiratory screening. According to the India State Level Disease Burden Initiative, chronic respiratory diseases accounted for around 10% of total disease burden in India in recent years, supporting demand for spirometry technologies.
The Japan digital spirometers market was valued at USD 20.97 million in 2025, supported by rapidly aging population, increasing prevalence of age-related respiratory disorders, and strong adoption of home-based healthcare solutions. The expansion of community-based elderly care models and preference for minimally invasive monitoring technologies are encouraging the use of compact digital respiratory assessment devices across healthcare settings.
The digital spirometers market competitive landscape is moderately consolidated, with competition concentrated among established medical device companies specializing in respiratory diagnostics, pulmonary function testing, and digital healthcare solutions. Leading players compete through technological innovation, measurement accuracy, and regulatory approvals. Emerging players focus on portable device development, remote monitoring features, and AI-based interpretation. The digital spirometers market ecosystem is shaped by advancements in respiratory care, increasing demand for digital diagnostic tools, and the need for efficient, connected lung function monitoring solutions.
March 2026: Strados Labs acquired NuvoAir Clinical Trials, adding remote and clinic-based digital spirometry, FeNO measurement, and electronic clinical outcome assessment (eCOA) capabilities to its respiratory trial platform.
September 2025: Norav Medical launched the Minispiro digital spirometer. The device introduced pulmonary function testing, EHR/HIS connectivity, pediatric testing support, and compliance with international spirometry standards to enhance respiratory diagnostics in clinical settings.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com